{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:13:36Z","timestamp":1790615616717,"version":"4.1.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/sap.0b013e31824e5e57","type":"journal-article","created":{"date-parts":[[2012,8,7]],"date-time":"2012-08-07T07:44:20Z","timestamp":1344325460000},"page":"434-440","source":"Crossref","is-referenced-by-count":54,"title":["Bevacizumab and Wound-Healing Complications"],"prefix":"10.1097","volume":"71","author":[{"given":"Ketan","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-26-20210203","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors.","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"R2-26-20210203","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications.","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"R3-26-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"key":"R4-26-20210203","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1024532022166","article-title":"Anti-angiogenic therapy: rationale, challenges and clinical studies.","volume":"5","author":"Longo","year":"2002","journal-title":"Angiogenesis"},{"key":"R6-26-20210203","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1345\/aph.1D470","article-title":"Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.","volume":"38","author":"Zondor","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R8-26-20210203","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1345\/aph.1L426","article-title":"Intricacies of bevacizumab-induced toxicities and their management.","volume":"43","author":"Gressett","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R9-26-20210203","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","article-title":"Understanding and managing the possible adverse effects associated with bevacizumab.","volume":"66","author":"Shord","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R10-26-20210203","doi-asserted-by":"crossref","first-page":"424","DOI":"10.12968\/bjon.2009.18.7.41657","article-title":"Adverse events in bevacizumab and chemotherapy: patient management.","volume":"18","author":"Blowers","year":"2009","journal-title":"Br J Nurs"},{"key":"R11-26-20210203","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2168.2002.02085.x","article-title":"Effect of venous ulcer exudates on angiogenesis in vitro.","volume":"89","author":"Drinkwater","year":"2002","journal-title":"Br J Surg"},{"key":"R12-26-20210203","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: an important warning to all surgeons.","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann Plast Surg"},{"key":"R13-26-20210203","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity.","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"R14-26-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1534734603256626","article-title":"The role of vascular endothelial growth factor in wound healing.","volume":"2","author":"Bates","year":"2003","journal-title":"Int J Low Extrem Wounds"},{"key":"R15-26-20210203","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJM199909023411006","article-title":"Cutaneous wound healing.","volume":"341","author":"Singer","year":"1999","journal-title":"N Engl J Med"},{"key":"R16-26-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jemt.10249","article-title":"Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix.","volume":"60","author":"Li","year":"2003","journal-title":"Microsc Res Tech"},{"key":"R17-26-20210203","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14712590902817817","article-title":"Bevacizumab: current indications and future development for management of solid tumors.","volume":"9","author":"Jenab-Wolcott","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"R19-26-20210203","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.cco.0000228734.32261.62","article-title":"Adverse effects of the humanized antibodies used as cancer therapeutics.","volume":"18","author":"Klastersky","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"R20-26-20210203","doi-asserted-by":"crossref","first-page":"53","DOI":"10.6004\/jnccn.2008.0006","article-title":"Chemotherapy for advanced, recurrent, and metastatic cervical cancer.","volume":"6","author":"Moore","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"R21-26-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/PPO.0b013e318161c014","article-title":"The role of angiogenesis inhibitors in prostate cancer.","volume":"14","author":"Aragon-Ching","year":"2008","journal-title":"Cancer J"},{"key":"R22-26-20210203","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"R23-26-20210203","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"R24-26-20210203","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer.","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"R25-26-20210203","doi-asserted-by":"crossref","first-page":"944","DOI":"10.12968\/bjon.2008.17.15.30695","article-title":"Managing patients with metastatic colorectal cancer on bevacizumab.","volume":"17","author":"Lemmens","year":"2008","journal-title":"Br J Nurs"},{"key":"R26-26-20210203","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"R27-26-20210203","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1200\/JCO.2009.21.9220","article-title":"Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.","volume":"27","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"key":"R28-26-20210203","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"key":"R29-26-20210203","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jamcollsurg.2007.06.290","article-title":"Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.","volume":"206","author":"Reddy","year":"2008","journal-title":"J Am Coll Surg"},{"key":"R30-26-20210203","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3171\/2010.10.JNS101042","article-title":"Impact of bevacizumab chemotherapy on craniotomy wound healing.","volume":"114","author":"Clark","year":"2011","journal-title":"J Neurosurg"},{"key":"R31-26-20210203","first-page":"733","article-title":"Does neoadjuvant bevacizumab increase surgical complications in breast surgery Ann Surg Oncol.","volume":"18","author":"Golshan","year":"2011","journal-title":""},{"key":"R32-26-20210203","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2008.21.3660","article-title":"Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.","volume":"27","author":"Jonasch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R33-26-20210203","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"R34-26-20210203","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"R35-26-20210203","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"R36-26-20210203","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(09)70341-9","article-title":"Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.","volume":"11","author":"Bose","year":"2010","journal-title":"Lancet Oncol"},{"key":"R37-26-20210203","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00384-009-0655-9","article-title":"A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.","volume":"24","author":"Cao","year":"2009","journal-title":"Int J Colorectal Dis"},{"key":"R38-26-20210203","first-page":"75597559","article-title":"Operative outcomes using bevacizumab, docetaxel, and cisplatin as induction therapy in patients with operable lung cancer.","volume":"27","author":"Finley","year":"2009","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R39-26-20210203","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","article-title":"Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.","volume":"26","author":"Gruenberger","year":"2008","journal-title":"J Clin Oncol"},{"key":"R40-26-20210203","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1200\/JCO.2008.17.7857","article-title":"Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.","volume":"26","author":"Kesmodel","year":"2008","journal-title":"J Clin Oncol"},{"key":"R41-26-20210203","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R42-26-20210203","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R43-26-20210203","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijrobp.2008.10.043","article-title":"Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.","volume":"75","author":"Gutin","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R44-26-20210203","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","article-title":"Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.","volume":"24","author":"Wedam","year":"2006","journal-title":"J Clin Oncol"},{"key":"R45-26-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3816\/CBC.2010.n.035","article-title":"Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.","volume":"10","author":"Forero-Torres","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"R46-26-20210203","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"R47-26-20210203","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"R48-26-20210203","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.juro.2008.03.047","article-title":"Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.","volume":"180","author":"Margulis","year":"2008","journal-title":"J Urol"},{"key":"R49-26-20210203","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"}],"container-title":["Annals of Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00000637-201310000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:41:03Z","timestamp":1618040463000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000637-201310000-00026"}},"subtitle":["Mechanisms of Action, Clinical Evidence, and Management Recommendations for the Plastic Surgeon"],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/sap.0b013e31824e5e57","relation":{},"ISSN":["0148-7043"],"issn-type":[{"value":"0148-7043","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}